Articles related to GUIDELINES/RECOMMENDATIONS

ACOG has revised its approach to postmenopausal bleeding evaluation, recommending combined transvaginal ultrasonography and endometrial sampling for most patients at initial presentation. The update reflects rising endometrial cancer incidence, evolving evidence on cancer subtypes, and recognized limitations of ultrasound-only evaluation.

The ACC updated its expert consensus pathway for HFpEF, emphasizing diagnostic scoring, comorbidity assessment, and newer cardiometabolic therapies. The pathway reflects emerging evidence while remaining aligned with existing heart failure guidelines.

The 2026 ACC/AHA dyslipidemia guideline reintroduces LDL-C treatment targets, expands risk assessment, and recommends universal Lp(a) screening. New analyses suggest many US adults now exceed recommended cholesterol thresholds, although treatment decisions remain individualized.

ASCO released updated recommendations for recurrent ovarian cancer that reinforce platinum-based doublet therapy as the preferred approach for platinum-sensitive disease and provide guidance for platinum-resistant disease, maintenance strategies, and monitoring. Recommendations were derived from a systematic review of studies published through 2025.

Accumulating evidence suggests that initiating effective therapy earlier in Crohn’s disease may reduce bowel damage progression, hospitalizations, and surgery. Long-term follow-up from recent studies has strengthened interest in a therapeutic window during which disease modification may be achievable.

A European Heart Journal debate revisits whether surgical aortic valve replacement should remain the preferred approach for patients with aortic stenosis and life expectancy beyond five years. Long-term durability and late procedural outcomes continue to shape the discussion.